|
rs121913465
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation.
|
28024692 |
2017 |
|
rs150423237
|
|
|
0.010 |
GeneticVariation |
BEFREE |
An adenocarcinoma patient with JM R675Q had erlotinib, 150 mg daily, added following progression of disease on carboplatin and paclitaxel and had a partial response for 4 months.
|
28573640 |
2017 |
|
rs397517108
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation.
|
28024692 |
2017 |
|
rs28929495
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Seven of 17 cases (41%) were reclassified in the adenocarcinoma with solid pattern group, which showed one KRAS G12C and one EGFR E709K + G719C double mutation in addition to mutations in TP53.
|
26430808 |
2016 |
|
rs2227983
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated the EGFR mutations and/or R497K polymorphism statuses in 225 surgically treated NSCLC cases.192 adenocarcinoma cases were included.
|
18726117 |
2009 |
|
rs146795390
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These observations suggest that the germline EGFR V843I mutation might have altered EGFR signaling in the multicentric development of adenocarcinoma, bronchoalveolar carcinoma, and atypical adenomatous hyperplasia and also might have had a role in the development of lung cancer in multiple members of her family.
|
18355544 |
2008 |
|
rs373129709
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of the present study was to investigate the relationship between EGF A61G genotype and EGF gene expression levels in colorectal adenocarcinomas and normal colon tissue.
|
17851837 |
2007 |
|
rs121913444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Tumor cells were separately collected from components of both the LCNEC and adenocarcinoma, and a mutational analysis of the epidermal growth factor receptor (EGFR) gene demonstrated that both components had the same L861Q mutation at exon 21.
|
23518631 |
2014 |
|
rs121913444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Seven months after initial diagnosis, the primary tumor enlarged again, and a second biopsy from the enlarged lesion detected only adenocarcinoma with the L861Q mutation.
|
24195468 |
2013 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Lung ADCA harbouring BRAF mutations are commonly non-V600E.
|
30591192 |
2019 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations.
|
31440061 |
2019 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAF(V600E) mutations, and 4 were non-BRAF(V600E) mutations.
|
25273224 |
2015 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Adenocarcinomas with this clinicopathologic phenotype may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge.
|
18636014 |
2008 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In exon 15, one BRAF mutation (1796 thymine to adenine; V599E) was found in nonsmoking woman with well-differentiated adenocarcinoma.
|
16376942 |
2006 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients.
|
31732945 |
2020 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After 12 mo of treatment with icotinib, ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790M mutation.
|
31363481 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We studied the prevalence of T790M mutation among pulmonary adenocarcinoma patients in Lebanese patients based on liquid biopsy testing the circulating tumor DNA (ctDNA).
|
31147859 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations.
|
30309763 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |